-The FDA has  cleared a platform (Catalys Precision, OptiMedica) combining a  femtosecond laser, optical coherence tomography imaging, and pattern scanning  technology to create single-plane and multi-plane arc incisions in the cornea  during cataract surgery.

The laser system, which received CE mark approval for these types of incisions  in March, also is cleared for capsulotomy and/or lens fragmentation in the  United States and the European Union. It has a proprietary interface (Liquid  Optics) designed to ensure stable system-patient attachment and optimization of  the optical path to the patient’s eye. The system also includes a proprietary  mapping system (Integral Guidance) meant to ensure that the femtosecond laser  pulses are delivered safely and precisely to the intended location. In  addition, it features a graphical user interface intended to simplify the  planning process and minimize the time patients are under the dock.

Since its international launch in November and its U.S. launch in  February, the system has been installed in more than 20 ophthalmic practices in  seven countries and has been used to perform more than 3,000 laser cataract  procedures.

“The  system represents a stark difference from first-generation laser cataract  surgery technologies in that it is very easy to use and has little to no  surgeon learning curve; delivers unparalleled precision and consistent  performance; and provides an enhanced experience for both surgeons and patients,”  said Mark J. Forchette, OptiMedica president and chief executive officer.

News

The FDA approved OptiMedica's Catalys Precision for creating single-plane and multi-plane arc incisions in the cornea during cataract surgery.